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With reference to the report by Nymark and colleagues,1 there are some points that 
should be highlighted. There is certainly a debate over whether methylphenidate is truly 
safe regarding possible cardiac side effects. However, the patient had taken quetiapine 
for 17 months. The association of cardiomyopathy and methylphenidate was high-
lighted while, as the authors mention, quetiapine may be related to cardiomyopathy. 
The 18-year-old boy with attention-deficit hyperactivity disorder (ADHD) had taken 
quetiapine 900 mg/day for the long period of 17 months while he was suffering from 
ADHD and overweight. It is clear that the authors visited the patient for the first time 
in their hospital while he had cardiogenic shock, oilguria, and raised liver enzymes.
There is limited research available on quetiapine. One of the side effects of these 
types of antipsychotics is metabolic syndrome that might increase cardiovascular 
events. So, in addition to the possible association of cardiomyopathy and methylpheni-
date, the adverse events of antipsychotics such as weight gain and metabolic syndrome 
should be carefully considered, especially in children and adolescents.2,3
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